ANGPT2 and age-related macular degeneration: Recently, the introduction of faricimab, a bi-specific antibody that simultaneously inhibits both VEGF-A and angiopoietin-2, has opened new avenues for treatment. Faricimab's dual mechanism of action may enhance its therapeutic effectiveness in managing CNVm related to AMD, as evidenced by promising clinical trial results [9].